alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

In the adult, angiogenesis, the formation of new blood vessels from pre-existing vasculature contributes to the pathogenesis of many disorders including cancer. The role of adhesion molecules, especially integrins, in pathological angiogenesis has long been the subject of investigation, mostly because of their potential as anti-angiogenic targets. Recent studies have highlighted the complexities connected with understanding the roles of one particular integrin, alphavbeta3, in neovascularization. This integrin is notoriously promiscuous and its precise functions in angiogenesis are unclear. Here, I have firstly summarized some of the salient features of the roles played by alphavbeta3 during angiogenesis; secondly attempted to address the apparently conflicting issues surrounding this topic; and finally raised some questions that appear to be unanswered.

[1]  Patrick T Caswell,et al.  Endocytic recycling pathways: emerging regulators of cell migration. , 2006, Current opinion in cell biology.

[2]  J. Qin,et al.  VEGF-integrin interplay controls tumor growth and vascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Wei Yan,et al.  Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. , 2008, Molecular biology of the cell.

[4]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis. , 1998 .

[5]  Daniel L. Gustafson,et al.  Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .

[6]  F. Ross,et al.  Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.

[7]  T. Byzova,et al.  Integrin signaling is critical for pathological angiogenesis , 2006, The Journal of experimental medicine.

[8]  R. Kalluri,et al.  Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties* , 2000, The Journal of Biological Chemistry.

[9]  J. Hickman,et al.  Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells , 2006 .

[10]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  O. Razorenova,et al.  Integrin affinity modulation in angiogenesis , 2008, Cell cycle.

[12]  Robert V Farese,et al.  Normal Development, Wound Healing, and Adenovirus Susceptibility in β5-Deficient Mice , 2000, Molecular and Cellular Biology.

[13]  D. Taverna,et al.  A Direct Test of Potential Roles for β3 and β5 Integrins in Growth and Metastasis of Murine Mammary Carcinomas , 2005 .

[14]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[16]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[17]  D. Hicklin,et al.  Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.

[18]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[19]  R. Soldi,et al.  Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2 , 1999, The EMBO journal.

[20]  R. Hynes,et al.  Novel Roles for α3β1 Integrin as a Regulator of Cytoskeletal Assembly and as a Trans-dominant Inhibitor of Integrin Receptor Function in Mouse Keratinocytes , 1998, The Journal of cell biology.

[21]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[22]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[23]  R. Kalluri.  Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. , 2002, Cold Spring Harbor symposia on quantitative biology.

[24]  M. U. Naik,et al.  Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin αvβ3 specific , 2006, Journal of Cell Science.

[25]  R. Hynes,et al.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. , 1999, The Journal of clinical investigation.

[26]  H. Friess,et al.  A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer , 2006, BMC Cancer.

[27]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[28]  R. Stupp,et al.  Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[30]  David A. Cheresh,et al.  Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins , 2001, The Journal of cell biology.

[31]  J. Roes,et al.  Ulcerative colitis and autoimmunity induced by loss of myeloid αv integrins , 2007, Proceedings of the National Academy of Sciences.

[32]  A. Reynolds,et al.  Integrins in angiogenesis: multitalented molecules in a balancing act , 2003, Cell and Tissue Research.

[33]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[34]  D. Cheresh,et al.  An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. , 1995, Journal of cell science.

[35]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[36]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[38]  D. Hicklin,et al.  &bgr;3-Integrin Regulates Vascular Endothelial Growth Factor-A–Dependent Permeability , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Hynes,et al.  Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins , 1998, Cell.

[40]  S. Baker,et al.  The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. , 2006, Cancer research.

[41]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[42]  M. Ginsberg,et al.  Trans-dominant inhibition of integrin function. , 1996, Molecular biology of the cell.

[43]  N. Killeen,et al.  Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function , 1999, Nature.

[44]  K. Alitalo,et al.  Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.

[45]  T. Byzova,et al.  Mechanisms of Integrin–Vascular Endothelial Growth Factor Receptor Cross-Activation in Angiogenesis , 2007, Circulation research.